The Effects of Bromelain Supplement in Patients With Ulcerative Colitis

National Nutrition and Food Technology Institute84 enrolled

Overview

In this study, patients with active mild to moderate UC with or without PSC will be randomized to receive either bromlein or placebo along with low FODMAP diet for 8 weeks. IBDQ, SCCAIQ, CRP, TAC, TNF-a will be measured before and after the intervention.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Ulcerative Colitis Primary Sclerosing Cholangitis

Interventions

BromleinDIETARY_SUPPLEMENT

1500 mg/day

PlaceboOTHER

Placebo (1500 mg/day)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: * active mild to moderate UC * no other chronic disorders Exclusion Criteria: * changed the type and dosage of their medication in the last month * those who have relapses that required hospitalization and change the type and dosage of medications during the intervention * patients who do not want to continue the study protocol

Locations (1)

Azita Hekmatdoost

Tehran, Middle East, Iran

RECRUITING